Drug intelligence / Profile preview

Standard ART + Mega ART

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Standard ART + Mega ART refers to a combination approach in antiretroviral therapy (ART) for HIV infection. "Standard ART" typically denotes the use of a recommended, evidence-based regimen consisting of at least three antiretroviral drugs from at least two different classes, designed to maximally suppress HIV replication and prevent disease progression[1][3][5]. "Mega ART" is not a standard term in clinical guidelines but is sometimes used informally or in research contexts to describe intensified regimens that include more than the usual number of antiretroviral agents—often four or more drugs, sometimes including additional drug classes or agents reserved for highly treatment-experienced patients with multidrug-resistant HIV. The rationale behind combining Standard and Mega regimens would be to achieve greater viral suppression in cases where resistance or advanced disease necessitates an aggressive approach. Mechanistically, these regimens act by targeting multiple stages of the HIV life cycle using various drug classes such as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), entry/fusion inhibitors, and others[8][10]. The specific composition depends on individual patient factors including prior treatment history and resistance patterns.

Other names
Standard ARTMega ART
02

Targets

CCR5 (C-C chemokine receptor type 5)Integrase allosteric pocket (HIV)PR (Progesterone receptor)Human immunodeficiency virus type 1 reverse transcriptasePOLG (Mitochondrial DNA polymerase gamma)

Beyond the preview

Go deeper on Standard ART + Mega ART.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Standard ART + Mega ART.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call